Q-omics provides the consensus-scored GATD1 profile across patient tissues and cancer cell-line models. GATD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GATD1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, GATD1 protein abundance shows 24,913 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, COAD, and PDAC as cancer lineages where GATD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GATD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GATD1 survival associations across molecular data types. GATD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GATD1 RNA expression–survival associations across cancer types. High GATD1 expression shows unfavorable associations in LIHC, KICH, ACC and LGG, but favorable associations in THYM and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GATD1 RNA expression.
This table summarizes GATD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GATD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GATD1 shows lower tumor expression in UCEC and higher tumor expression in COAD, LIHC, STAD, CHOL and READ. The COAD box plot shows higher GATD1 RNA expression in tumor versus normal tissue (log2 FC = +1.336, t-test p < 0.001).
This table shows molecular features associated with GATD1 in patient tissues and cancer cell lines. In patient samples, GATD1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GATD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
